TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Hours alive with normal pH (≥ 7.35)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak power output (PPO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with controlled blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of phenylalanine (Phe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Technical performance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance of patients
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Occlusion of the feeding arteries and veins confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cosmetic outcome according to the modified Hollandar scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Amount of cfDNA/NETs in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Free throw shooting self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline heartbeat evoked potential (HEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Frequency of Naloxone Utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Aesthetic quality of the scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Evaluation of the effect of pain on functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Evaluation of the level of functional disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence or absence of signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Mean Nasal Obstruction Visual Analogue Scale (VAS) Score During the 4 Weeks Prior to Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADAS-Cog total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in the Gesell Developmental Scale (GDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Infants-Junior High School Students' Social Development Screening Test
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful organ preservation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Experiencing a Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cancer prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Total Lean Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: injection site pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence rate of injection site reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Time for Train-Of-Four (TOF) ratio to reach 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of seconds in an alert condition state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of Tucatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AFib detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in spot urine albumin-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in spot urine protein-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Complete resection of FIGO II fibroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to Sustained Resolution of COVID-19 Signs and Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total score of PSP-rating scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change in viscoelastic hemostasis parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impulsivity measured by UPPS- Behavioral Impulsive scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under plasma concentration-time curve from zero to infinity (AUCinf) of capivasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma (peak) drug concentration (Cmax) of capivasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Clinically Significant Hematomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants with Clinically Significant Seromas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Patient Drain Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of non-major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall adherence to recommended care pathway
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Prostate Cancer Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in the level of inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with ANY intracerebral hemorrhage (ICH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stroke severity as measured by the National Institutes of Health Stroke Scale (NIHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: outcome of patients admitted to the Intensive Care Unit
Endpoint domain: Mortality/survival
Primary endpoint: Change in social connection
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in daily experiences
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Changes in daily well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self Reported Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Ritchie Articular Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: daily intake using 24-hour Dietary Recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: salicylates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: angiogenesis biomarker: sFLT1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angiogenesis biomarker: VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angiogenesis biomarker: PLGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STOX-1 protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of bioimpedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Empiric Extended-Spectrum Days of Therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IYCF knowledge and practice scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage of patients not required blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in active shoulder ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in functional performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient adherence to protocol defined DBS time points
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of in-home DBS samples passing quality assurance checks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plaque characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in volume and echogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in LARS symptom scores with transanal irrigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in LARS symptom scores with best supportive treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simulated keratometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Modified Mini Mental Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The Central Nervous System Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor Function Measurement-32 Items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Autonomic Symptom Score-31
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: r-r interval variability with normal breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: blood pressure response to standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with weight loss and cachexia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Potential renal acid load (PRAL) in mEq/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dynamic cerebral autoregulation parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pressure Ulcer Scale for Healing (PUSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of movement-evoked pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated Glomerular Filtration rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Albumin-to-Creatinine ratio (ACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Acute Radiation Dermatitis grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Tumor burden correlation with GC and LC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plexiform neurofibroma burden change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Fear of Cancer Recurrence Inventory (FCRI) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progression-Free Survival (PFS-12)
Endpoint domain: Mortality/survival
Primary endpoint: Maternal Serum Stathmin-1 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment acceptability measured by CSQ-8
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of completion of the CF-CBT-A program sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Baseline swelling using Figure-8 Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean swelling using Figure-8 Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise Adherence Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in cross-sectional area of the rectus femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Particle concentration measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mass concentration measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioaerosol measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Potentially Clinically Serious (PCS) Change from Baseline in Clinical Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Columbia Suicide Severity Rating Scale (C-SSRS) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Blood Functional Alpha-1 Antitrypsin (AAT) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnostic accuracy of measurement methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight of 1-hour pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEST Scale Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Lens Removal Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Amount of Irrigation Solution Fluid Volume Used During the Surgical Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Wexner incontinence score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence and Grade of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Lactate measurement comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Troponin-T measurement comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Predictive performance for Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Perirectal distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPADI (shoulder pain and disability index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximal stent overexpansion (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of lymphoscintigraphic examination and SLN biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Visual Acuity during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-frequency vestibulo-ocular reflex restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait stability and balance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper limb Fugl Meyer motor assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stroke specific quality of life (SSQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visual analog scale-pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single leg-hop test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary diffusion of piperacillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of activity of SLE and RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of ERAS protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of ERAS protocol
Endpoint domain: Adverse events/effects
Primary endpoint: Exercise-induced change in affective valence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plaque Control Record Evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of the Réunion mutation in the BRCA2 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of Life and Functional Disability Improvements
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Healthcare Cost Reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rapid osseintegration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inclusion of Other in the Self Scale (IOS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: UCLA Loneliness Scale (ULS-6)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relational Health Indices (RHI)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Quantitative Program Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of health workers infected with SARS-CoV-2
Endpoint domain: Adverse events/effects
Primary endpoint: Seroprevalence of SARS-CoV-2 infection among pregnant women
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability measured by adherence to intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Appropriateness measured by retention rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility measured by enrollment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SENS-401 perilymph detection percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Survival rate at discharge or 30 days after weaning from ventilator
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of major adverse events at discharge or 30 days after weaning
Endpoint domain: Adverse events/effects
Primary endpoint: Predictive capacity of the ED-PSTGP questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Group P-S
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Word form recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word meaning recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Form-referent-link recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypoglycemia incidence rate
Endpoint domain: Adverse events/effects
Primary endpoint: anterior-posterior and medio-lateral sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total score from archers shots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with undetectable viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with low self-stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absence of revisions, reoperations, and implant loosening
Endpoint domain: Adverse events/effects
Primary endpoint: VAS anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to first COPD Composite Exacerbation (CompEx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with radiologic stone recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: clicking sounds frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dutch Eating Behavior Questionnaire (DEBQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in functional class of chronic heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence to quality-of-care indicators
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC from timepoint 0 to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of total radioactivity (TRA) recovered in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes